On the Record · Bausch & Lomb
Bausch & Lomb acquisitions, on the record
The businesses Bausch & Lomb bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.
Deals its annual reports describe
| Business | Deal | When | Value |
|---|---|---|---|
XIIDRA ® and certain other ophthalmology assets from Novartis Pharma AG and Novartis Finance CorporationWord for word“We have recently completed a number of acquisitions and in-licensing transactions, including our recent acquisition of XIIDRA ® (lifitegrast ophthalmic solution) and certain other ophthalmology assets from Novartis Pharma AG and Novartis Finance Corporation (the “XIIDRA Acquisition”) .” 10-K for 2023 | agreed acquisition | — | — |
XIIDRA and certain other ophthalmology assetsWord for word“We completed our acquisition of XIIDRA ® during the third quarter of 2023.” 10-K for 2024 | acquisition | We completed our acquisition of XIIDRA ® during the third quarter of 2023. | — |
TearLab Corporation, d/b/a Trukera Medical ("Trukera Medical")Word for word“and our recent acquisitions of TearLab Corporation, d/b/a Trukera Medical (“Trukera Medical”), Elios Vision, Inc. ("Elios Vision") and Whitecap Biosciences, LLC, ("Whitecap Biosciences")), including risks that we may not realize the expected benefits of such acquisitions and transactions on a timely basis or at all, risks that pipeline products acquired may not be commercialized as anticipated, and risks relating to any increased levels of debt as a result of debt incurred to finance certain of these acquisitions and transactions;” 10-K for 2024 | acquisition | — | — |
Blink OTC product line from Johnson & Johnson VisionWord for word“In July 2023, we acquired the Blink ® OTC product line of eye and contact lens drops from Johnson & Johnson Vision, which consists of Blink ® Tears Lubricating Eye Drops, Blink ® Tears Preservative Free Lubricating Eye Drops, Blink GelTears ® Lubricating Eye Drops, Blink ® Triple Care 2 Lubricating Eye Drops, Blink Contacts ® Lubricating Eye Drops and Blink-N-Clean ® Lens Drops (collectively, the “Blink ® Product Line”).” 10-K for 2024 | acquisition | In July 2023 | — |
The Company (potential sale of Bausch + Lomb, explored by its Board)Word for word“For example, on December 12, 2024, we announced that the Board of Directors authorized management and its advisors to explore a potential sale of the Company, as one of several options being explored to complete the Separation.” 10-K for 2024 | agreed divestiture | On December 12, 2024 | — |
XIIDRAWord for word“We completed our acquisition of XIIDRA ® during the third quarter of 2023.” 10-K for 2025 | acquisition | during the third quarter of 2023 | — |
| Fiscal year ended | Goodwill from acquisitions |
|---|---|
| 2022-12-31 | $5 million |
| 2023-12-31 | $31 million |
| 2024-12-31 | $29 million |
| 2025-12-31 | $97 million |
Deal filings since 2016
- 2026-08-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2026-01-02 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2025-06-27 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2024-11-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-09-29 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2023-09-29 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
- 2023-07-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-06-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
- 2022-05-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
Read from Bausch & Lomb’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-02-18. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.